New topical microemulsions of etofenamate as sufficient management of osteoarthritis

Detalhes bibliográficos
Autor(a) principal: Üstündağ Okur, Neslihan
Data de Publicação: 2022
Outros Autores: Onay, Ecehan, Kadıoğlu Yaman, Beril, Sipahi, Hande
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Brazilian Journal of Pharmaceutical Sciences
Texto Completo: https://www.revistas.usp.br/bjps/article/view/205308
Resumo: In this study, microemulsions containing etofenamate were prepared and evaluated as dermal delivery carriers. The developed microemulsions consist of oleic acid, Span 80, Tween 20, Cremophor EL, Transcutol and ethanol. The percentage of etofenamate loading in the microemulsions was 5% (w/w). The characterization of formulations included droplet size, zeta potential, pH, conductivity, PDI, refractive index and viscosity. Moreover, ex vivo penetration study was carried out using mice abdominal skin. The developed formulations were analyzed for their cytotoxicity via MTT assay and tested for their anti-inflammatory properties opposed to LPS-stimulated nitrite prοduction in RAW 264.7 cells. As ideal formulation, M2ETF, was chosen due to its greater permeation, lower penetration as well as higher anti-inflammatory activity compared to other microemulsions.
id USP-31_477350bc308c4c887719c8cf71e7a87b
oai_identifier_str oai:revistas.usp.br:article/205308
network_acronym_str USP-31
network_name_str Brazilian Journal of Pharmaceutical Sciences
repository_id_str
spelling New topical microemulsions of etofenamate as sufficient management of osteoarthritisEtofenamateNonsteroidal anti-inflammatory drugMicroemulsionEx vivoCytotoxicityAnti-inflammatory activityIn this study, microemulsions containing etofenamate were prepared and evaluated as dermal delivery carriers. The developed microemulsions consist of oleic acid, Span 80, Tween 20, Cremophor EL, Transcutol and ethanol. The percentage of etofenamate loading in the microemulsions was 5% (w/w). The characterization of formulations included droplet size, zeta potential, pH, conductivity, PDI, refractive index and viscosity. Moreover, ex vivo penetration study was carried out using mice abdominal skin. The developed formulations were analyzed for their cytotoxicity via MTT assay and tested for their anti-inflammatory properties opposed to LPS-stimulated nitrite prοduction in RAW 264.7 cells. As ideal formulation, M2ETF, was chosen due to its greater permeation, lower penetration as well as higher anti-inflammatory activity compared to other microemulsions.Universidade de São Paulo. Faculdade de Ciências Farmacêuticas2022-12-23info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://www.revistas.usp.br/bjps/article/view/20530810.1590/s2175-97902022e20123Brazilian Journal of Pharmaceutical Sciences; Vol. 58 (2022)Brazilian Journal of Pharmaceutical Sciences; v. 58 (2022)Brazilian Journal of Pharmaceutical Sciences; Vol. 58 (2022)2175-97901984-8250reponame:Brazilian Journal of Pharmaceutical Sciencesinstname:Universidade de São Paulo (USP)instacron:USPenghttps://www.revistas.usp.br/bjps/article/view/205308/194914Copyright (c) 2022 Brazilian Journal of Pharmaceutical Scienceshttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessÜstündağ Okur, NeslihanOnay, EcehanKadıoğlu Yaman, BerilSipahi, Hande2023-06-07T14:02:16Zoai:revistas.usp.br:article/205308Revistahttps://www.revistas.usp.br/bjps/indexPUBhttps://old.scielo.br/oai/scielo-oai.phpbjps@usp.br||elizabeth.igne@gmail.com2175-97901984-8250opendoar:2023-06-07T14:02:16Brazilian Journal of Pharmaceutical Sciences - Universidade de São Paulo (USP)false
dc.title.none.fl_str_mv New topical microemulsions of etofenamate as sufficient management of osteoarthritis
title New topical microemulsions of etofenamate as sufficient management of osteoarthritis
spellingShingle New topical microemulsions of etofenamate as sufficient management of osteoarthritis
Üstündağ Okur, Neslihan
Etofenamate
Nonsteroidal anti-inflammatory drug
Microemulsion
Ex vivo
Cytotoxicity
Anti-inflammatory activity
title_short New topical microemulsions of etofenamate as sufficient management of osteoarthritis
title_full New topical microemulsions of etofenamate as sufficient management of osteoarthritis
title_fullStr New topical microemulsions of etofenamate as sufficient management of osteoarthritis
title_full_unstemmed New topical microemulsions of etofenamate as sufficient management of osteoarthritis
title_sort New topical microemulsions of etofenamate as sufficient management of osteoarthritis
author Üstündağ Okur, Neslihan
author_facet Üstündağ Okur, Neslihan
Onay, Ecehan
Kadıoğlu Yaman, Beril
Sipahi, Hande
author_role author
author2 Onay, Ecehan
Kadıoğlu Yaman, Beril
Sipahi, Hande
author2_role author
author
author
dc.contributor.author.fl_str_mv Üstündağ Okur, Neslihan
Onay, Ecehan
Kadıoğlu Yaman, Beril
Sipahi, Hande
dc.subject.por.fl_str_mv Etofenamate
Nonsteroidal anti-inflammatory drug
Microemulsion
Ex vivo
Cytotoxicity
Anti-inflammatory activity
topic Etofenamate
Nonsteroidal anti-inflammatory drug
Microemulsion
Ex vivo
Cytotoxicity
Anti-inflammatory activity
description In this study, microemulsions containing etofenamate were prepared and evaluated as dermal delivery carriers. The developed microemulsions consist of oleic acid, Span 80, Tween 20, Cremophor EL, Transcutol and ethanol. The percentage of etofenamate loading in the microemulsions was 5% (w/w). The characterization of formulations included droplet size, zeta potential, pH, conductivity, PDI, refractive index and viscosity. Moreover, ex vivo penetration study was carried out using mice abdominal skin. The developed formulations were analyzed for their cytotoxicity via MTT assay and tested for their anti-inflammatory properties opposed to LPS-stimulated nitrite prοduction in RAW 264.7 cells. As ideal formulation, M2ETF, was chosen due to its greater permeation, lower penetration as well as higher anti-inflammatory activity compared to other microemulsions.
publishDate 2022
dc.date.none.fl_str_mv 2022-12-23
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://www.revistas.usp.br/bjps/article/view/205308
10.1590/s2175-97902022e20123
url https://www.revistas.usp.br/bjps/article/view/205308
identifier_str_mv 10.1590/s2175-97902022e20123
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv https://www.revistas.usp.br/bjps/article/view/205308/194914
dc.rights.driver.fl_str_mv Copyright (c) 2022 Brazilian Journal of Pharmaceutical Sciences
https://creativecommons.org/licenses/by/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Copyright (c) 2022 Brazilian Journal of Pharmaceutical Sciences
https://creativecommons.org/licenses/by/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Universidade de São Paulo. Faculdade de Ciências Farmacêuticas
publisher.none.fl_str_mv Universidade de São Paulo. Faculdade de Ciências Farmacêuticas
dc.source.none.fl_str_mv Brazilian Journal of Pharmaceutical Sciences; Vol. 58 (2022)
Brazilian Journal of Pharmaceutical Sciences; v. 58 (2022)
Brazilian Journal of Pharmaceutical Sciences; Vol. 58 (2022)
2175-9790
1984-8250
reponame:Brazilian Journal of Pharmaceutical Sciences
instname:Universidade de São Paulo (USP)
instacron:USP
instname_str Universidade de São Paulo (USP)
instacron_str USP
institution USP
reponame_str Brazilian Journal of Pharmaceutical Sciences
collection Brazilian Journal of Pharmaceutical Sciences
repository.name.fl_str_mv Brazilian Journal of Pharmaceutical Sciences - Universidade de São Paulo (USP)
repository.mail.fl_str_mv bjps@usp.br||elizabeth.igne@gmail.com
_version_ 1800222916591222784